Proteolytic enzyme activity in patients with severe head injury and the effect of a proteinase inhibitor.
A study was performed to detect the inhibitory effect of intravenously administered aprotinin (Trasylol) on brain and CSF protease activity in 25 patients with severe head injury. The data presented include measurements of CSF protease activity, alpha-1-antitrypsin, alpha-2-macroglobulin, haptoglobulin, polyacrylamidgel-electrophoresis pattern, total protein and hemoglobin content. The results indicate that increased protease activity is present and that this induces autolytic processes which can be inhibited by aprotinin treatment. The survival rate was higher after aprotinin treatment. Total CSF protein content was significantly higher in nonsurvivors than in survivors.
D007611:Aprotinin / Q000494:pharmacology*; D001812:Blood-Brain Barrier; D001930:Brain Injuries / Q000134:cerebrospinal fluid / Q000201:enzymology*; D006801:Humans; D011480:Protease Inhibitors / Q000134:cerebrospinal fluid* / Q000378:metabolism; D000515:alpha 1-Antitrypsin / Q000134:cerebrospinal fluid; D000511:alpha-Macroglobulins / Q000134:cerebrospinal fluid
D011480:Protease Inhibitors; D000515:alpha 1-Antitrypsin; D000511:alpha-Macroglobulins; D007611:Aprotinin